Trial Profile
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Nazartinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 26 Jun 2023 This trial has been completed in Netherlands, according to the European Clinical Trials Database record.
- 22 May 2023 Planned End Date changed from 8 Jun 2023 to 21 Jul 2023.
- 18 Apr 2023 This trial has been suspended in Netherlands, according to the European Clinical Trials Database record.